What is the address of Fré Pharma?

The registered office of Fré Pharma is located at Bierbeekstraat 2B box 1, 3052 Oud-Heverlee.

Is Fré Pharma still active?

Yes. According to the CBE (31 October 2026) Fré Pharma is active, legal situation “Normale toestand”, started on 26 September 2012.

Is Fré Pharma registered on Peppol?

Yes, Fré Pharma is registered on the Peppol network with ID 0208:0849038129.

What is the enterprise number of Fré Pharma?

The enterprise number of Fré Pharma is BE0849038129.

When was Fré Pharma founded?

Fré Pharma was founded on 26 September 2012.

Who are the directors of Fré Pharma?

According to the 2025 annual accounts, the directors of Fré Pharma are: Fréderic Hertens.

Is Fré Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 September 2012; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Fré Pharma make in 2025?

Fré Pharma posted a profit after taxes of € 40,263 in financial year 2025.

What is the revenue of Fré Pharma?

As a small company, Fré Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 78,271.

Fré Pharma (Private Limited) - Oud-Heverlee

Q: What does Fré Pharma do?

Fré Pharma is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 26 September 2012, 1 establishment.

Dossier Fré Pharma, printed on 31 October 2026 from databakkes.be/en/0849038129/fre-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 7 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Fré Pharma from Oud-Heverlee, company number BE0849038129, closed financial year 2025 with a result of € 40,263 after tax. For that financial year Fré Pharma recorded a gross margin of € 78,271 and equity of € 546,583. Compared with financial year 2024, the result moved from € 38,114 to € 40,263. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2025.

What it is worth Growing

€ 546,583

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 40,263

▲ 6% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 14,608

▲ 49% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 496,583.

People and assets in 2025

Vehicles and equipment

€ 2,622

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 318,243

▼ 24% vs 2024

€ 103,251 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 10,958

▲ 86% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 32,171

▲ 200% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 182,906 Gross margin 2022: € 182,906 First fiscal year in the series	€ 69,159 Gross margin 2023: € 69,159 ▼ 62% vs 2022 (€ 182,906) Unfavourable step	€ 68,455 Gross margin 2024: € 68,455 ▼ 1% vs 2023 (€ 69,159) Unfavourable step	€ 78,271 Gross margin 2025: € 78,271 ▲ 14% vs 2024 (€ 68,455) Favourable step	▲ 14%
Profit after taxes	€ 121,812 Profit after taxes 2022: € 121,812 First fiscal year in the series	€ 37,833 Profit after taxes 2023: € 37,833 ▼ 69% vs 2022 (€ 121,812) Unfavourable step	€ 38,114 Profit after taxes 2024: € 38,114 ▲ 1% vs 2023 (€ 37,833) Favourable step	€ 40,263 Profit after taxes 2025: € 40,263 ▲ 6% vs 2024 (€ 38,114) Favourable step	▲ 6%
Equity	€ 430,373 Equity 2022: € 430,373 First fiscal year in the series	€ 468,205 Equity 2023: € 468,205 ▲ 9% vs 2022 (€ 430,373) Favourable step	€ 506,320 Equity 2024: € 506,320 ▲ 8% vs 2023 (€ 468,205) Favourable step	€ 546,583 Equity 2025: € 546,583 ▲ 8% vs 2024 (€ 506,320) Favourable step	▲ 8%
Total debts	€ 1,556,007 Total debts 2022: € 1,556,007 First fiscal year in the series	€ 1,182,433 Total debts 2023: € 1,182,433 ▼ 24% vs 2022 (€ 1,556,007) Favourable step	€ 739,133 Total debts 2024: € 739,133 ▼ 37% vs 2023 (€ 1,182,433) Favourable step	€ 714,144 Total debts 2025: € 714,144 ▼ 3% vs 2024 (€ 739,133) Favourable step	▼ 3%
Cash	€ 4 Cash 2022: € 4 First fiscal year in the series	€ 20,692 Cash 2023: € 20,692 ▲ € 20,688 vs 2022 (€ 4) Favourable step	€ 9,828 Cash 2024: € 9,828 ▼ 53% vs 2023 (€ 20,692) Unfavourable step	€ 14,608 Cash 2025: € 14,608 ▲ 49% vs 2024 (€ 9,828) Favourable step	▲ 49%
Land & buildings	€ 408,110 Land & buildings 2022: € 408,110 First fiscal year in the series	€ 408,110 Land & buildings 2023: € 408,110 Unchanged (€ 408,110) Unchanged	€ 4,726 Land & buildings 2024: € 4,726 ▼ 99% vs 2023 (€ 408,110) Unchanged	€ 4,726 Land & buildings 2025: € 4,726 Unchanged (€ 4,726) Unchanged
Retained profit	€ 380,373 Retained profit 2022: € 380,373 First fiscal year in the series	€ 418,205 Retained profit 2023: € 418,205 ▲ 10% vs 2022 (€ 380,373) Favourable step	€ 456,320 Retained profit 2024: € 456,320 ▲ 9% vs 2023 (€ 418,205) Favourable step	€ 496,583 Retained profit 2025: € 496,583 ▲ 9% vs 2024 (€ 456,320) Favourable step	▲ 9%
Bank debt	€ 1,028,612 Bank debt 2022: € 1,028,612 First fiscal year in the series	€ 626,433 Bank debt 2023: € 626,433 ▼ 39% vs 2022 (€ 1,028,612) Favourable step	€ 418,112 Bank debt 2024: € 418,112 ▼ 33% vs 2023 (€ 626,433) Favourable step	€ 318,243 Bank debt 2025: € 318,243 ▼ 24% vs 2024 (€ 418,112) Favourable step	▼ 24%
Balance sheet total	€ 1,986,379 Balance sheet total 2022: € 1,986,379 First fiscal year in the series	€ 1,650,639 Balance sheet total 2023: € 1,650,639 ▼ 17% vs 2022 (€ 1,986,379) Unchanged	€ 1,245,453 Balance sheet total 2024: € 1,245,453 ▼ 25% vs 2023 (€ 1,650,639) Unchanged	€ 1,260,727 Balance sheet total 2025: € 1,260,727 ▲ 1% vs 2024 (€ 1,245,453) Unchanged	▲ 1%

Key figures of Fré Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2026 has not been filed yet; it was expected before 31 October 2026.

What happened to Fré Pharma?

What happened at Fré Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 29, 2025 New annual accounts for financial year 2025: profit of € 40,263 (▲ 6% vs 2024). Source: NBB ↗
Sep 1, 2017 New establishment in Oud-Heverlee. KBO
2012 Fréderic Hertens became a director. NBB
Sep 26, 2012 Start of the company according to the CBE. KBO

In short

From € 121,812 profit in 2022 to € 40,263 profit in 2025.

Paid € 83,665 in corporate taxes since 2022.

Best year ever: 2022, with € 121,812 profit.

Original PDFs at the National Bank ↗

Management

Fréderic Hertens

Fré Pharma

Apotheek Meerdaal 100%

Behind Fré Pharma is Fréderic Hertens. It owns 100% of Apotheek Meerdaal itself.

Directors

According to the 2025 annual accounts

Fréderic Hertens

Director

since 2012

Establishments

Establishment units

Physical locations of this company

Registered office

Bierbeekstraat 2B box 1

3052 Oud-Heverlee

2.268.324.115

Bierbeekstraat 1

3052 Oud-Heverlee

Active since 1 September 2017

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

APOTHEEK MEERDAAL same network

€ 300,429 gross margin · 2025

Dokter Marijke Vanderstappen

€ 192,434 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0849.038.129

VAT number

BE 0849.038.129

Registered office

Bierbeekstraat 2B bus 1, 3052 Oud-Heverlee

Names & denominations

Fré Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

26 September 2012

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

Fré Pharma

Warning lights

Financials

What happened to Fré Pharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions